Incyte on Monday announced that its experimental drug has met the main goal in two separate late-stage studies testing it. The studies were conducted on patients with an inflammatory skin condition called hidradenitis suppurativa.
The oral drug, povorcitinib, helped reduce symptoms of the condition by at least 50 percent in a significant number of patients after 12 weeks, when measured on a commonly used scale.
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for prurigo nodularis (PN). Phase 2 studies of povorcitinib in PN, asthma and chronic spontaneous urticaria are also ongoing, the company stated.
Hidradenitis suppurativa is an acne-like condition that causes painful bumps and lesions in and under the skin.
(With inputs from Reuters)
